Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Journal of Cardiovascular Translational Research
Erschienen in: Journal of Cardiovascular Translational Research 5/2018

09.05.2018 | Review Paper

Regenerative Therapy for Cardiomyopathies

verfasst von: Zi Wang, Xuan Su, Muhammad Ashraf, Il-man Kim, Neal L. Weintraub, Meng Jiang, Yaoliang Tang

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Despite substantial advances in the development of medical and interventional strategies in ischemic and non-ischemic heart diseases, cardiovascular diseases (CVDs) remain the leading cause of mortality and morbidity worldwide. Stem cell therapy for heart disease has gained traction over the past two decades and is an emerging option for the treatment of myocardial dysfunction. In this review, we summarize the current literature on different types of stem cells and their potential usage in ischemic and non-ischemic heart diseases. We emphasize the clinical utility of stem cells to improve myocardial structural and function, promote microvascular angiogenesis, and diminish scar size and major adverse cardiovascular events. We also discuss the therapeutic potential of microvesicles, such as exosomes, in the treatment of CVDs, which may open novel avenues for further clinical studies.
Literatur
1.
Sun, R., Li, X., Liu, M., Zeng, Y., Chen, S., & Zhang, P. (2016). Advances in stem cell therapy for cardiovascular disease (review). International Journal of Molecular Medicine, 38(1), 23–29.PubMedPubMedCentral
2.
Trindade, F., Leite-Moreira, A., Ferreira-Martins, J., Ferreira, R., Falcao-Pires, I., & Vitorino, R. (2017). Towards the standardization of stem cell therapy studies for ischemic heart diseases: bridging the gap between animal models and the clinical setting. International Journal of Cardiology, 228, 465–480.PubMed
3.
Bernstein, H. S., & Srivastava, D. (2012). Stem cell therapy for cardiac disease. Pediatric Research, 71(4 Pt 2), 491–499.PubMed
4.
Moreira, M. L., da Costa Medeiros, P., de Souza, S. A., Gutfilen, B., & Rosado-de-Castro, P. H. (2016). In vivo tracking of cell therapies for cardiac diseases with nuclear medicine. Stem Cells International, 2016, 3140120.PubMedPubMedCentral
5.
Silva, G. V., Litovsky, S., Assad, J. A., Sousa, A. L., Martin, B. J., Vela, D., et al. (2005). Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation, 111(2), 150–156.PubMed
6.
Nagaya, N., Kangawa, K., Itoh, T., Iwase, T., Murakami, S., Miyahara, Y., et al. (2005). Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation, 112(8), 1128–1135.PubMed
7.
Fernandes, S., Chong, J. J., Paige, S. L., Iwata, M., Torok-Storb, B., Keller, G., et al. (2015). Comparison of human embryonic stem cell-derived cardiomyocytes, cardiovascular progenitors, and bone marrow mononuclear cells for cardiac repair. Stem Cell Reports, 5(5), 753–762.PubMedPubMedCentral
8.
Jiang, M., Mao, J., & He, B. (2012). The effect of bone marrow-derived cells on diastolic function and exercise capacity in patients after acute myocardial infarction. Stem Cell Research, 9(1), 49–57.PubMed
9.
Bolli, R., Chugh, A. R., D'Amario, D., Loughran, J. H., Stoddard, M. F., Ikram, S., et al. (2011). Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet, 378(9806), 1847–1857.PubMedPubMedCentral
10.
Hare, J. M., Fishman, J. E., Gerstenblith, G., DiFede Velazquez, D. L., Zambrano, J. P., Suncion, V. Y., et al. (2012). Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. Journal of the American Medical Association, 308(22), 2369–2379.PubMed
11.
Lee, C. Y., Kim, R., Ham, O., Lee, J., Kim, P., Lee, S., et al. (2016). Therapeutic potential of stem cells strategy for cardiovascular diseases. Stem Cells International, 2016, 4285938.PubMedPubMedCentral
12.
Geng, Y. J. (2003). Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Annals of the New York Academy of Sciences., 1010, 687–697.PubMed
13.
Yu, H., Lu, K., Zhu, J., & Wang, J. (2017). Stem cell therapy for ischemic heart diseases. British Medical Bulletin, 121(1), 135–154.PubMed
14.
Shen, H., Wang, Y., Zhang, Z., Yang, J., Hu, S., & Shen, Z. (2015). Mesenchymal stem cells for cardiac regenerative therapy: optimization of cell differentiation strategy. Stem Cells International, 2015, 524756.PubMedPubMedCentral
15.
Strauer, B. E., Brehm, M., Zeus, T., Gattermann, N., Hernandez, A., Sorg, R. V., et al. (2001). [Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction]. Deutsche Medizinische Wochenschrift, 126(34–35), 932–938.PubMed
16.
Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Holschermann, H., et al. (2006). Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. The New England Journal of Medicine, 355(12), 1210–1221.PubMed
17.
Shiba, Y., Fernandes, S., Zhu, W. Z., Filice, D., Muskheli, V., Kim, J., et al. (2012). Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature, 489(7415), 322–325.PubMedPubMedCentral
18.
Jin, P., Li, T., Li, X., Shen, X., & Zhao, Y. (2016). Suppression of oxidative stress in endothelial progenitor cells promotes angiogenesis and improves cardiac function following myocardial infarction in diabetic mice. Experimental and Therapeutic Medicine, 11(6), 2163–2170.PubMedPubMedCentral
19.
Wu, Y., Ip, J. E., Huang, J., Zhang, L., Matsushita, K., Liew, C. C., et al. (2006). Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. Circulation Research, 99(3), 315–322.PubMed
20.
Kawamura, M., Miyagawa, S., Fukushima, S., Saito, A., Miki, K., Ito, E., et al. (2013). Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation, 128(11 Suppl 1), S87–S94.PubMed
21.
Tang, Y. L., Zhu, W., Cheng, M., Chen, L., Zhang, J., Sun, T., et al. (2009). Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circulation Research, 104(10), 1209–1216.PubMedPubMedCentral
22.
Afzal, M. R., Samanta, A., Shah, Z. I., Jeevanantham, V., Abdel-Latif, A., Zuba-Surma, E. K., et al. (2015). Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circulation Research, 117(6), 558–575.PubMedPubMedCentral
23.
Mangi, A. A., Noiseux, N., Kong, D., He, H., Rezvani, M., Ingwall, J. S., et al. (2003). Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nature Medicine, 9(9), 1195–1201.PubMed
24.
Matsui, T., Tao, J., del Monte, F., Lee, K. H., Li, L., Picard, M., et al. (2001). Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation, 104(3), 330–335.PubMed
25.
Huang, J., Guo, J., Beigi, F., Hodgkinson, C. P., Facundo, H. T., Zhang, Z., et al. (2014). HASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotection. Journal of Molecular and Cellular Cardiology, 66, 157–164.PubMed
26.
Aonuma, T., Takehara, N., Maruyama, K., Kabara, M., Matsuki, M., Yamauchi, A., et al. (2016). Apoptosis-resistant cardiac progenitor cells modified with apurinic/apyrimidinic endonuclease/redox factor 1 gene overexpression regulate cardiac repair after myocardial infarction. Stem Cells Translational Medicine, 5(8), 1067–1078.PubMedPubMedCentral
27.
Karantalis, V., Suncion-Loescher, V. Y., Bagno, L., Golpanian, S., Wolf, A., Sanina, C., et al. (2015). Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy. Journal of the American College of Cardiology, 66(18), 1990–1999.PubMedPubMedCentral
28.
Williams, A. R., Hatzistergos, K. E., Addicott, B., McCall, F., Carvalho, D., Suncion, V., et al. (2013). Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation, 127(2), 213–223.PubMed
29.
Avolio, E., Meloni, M., Spencer, H. L., Riu, F., Katare, R., Mangialardi, G., et al. (2015). Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair. Circulation Research, 116(10), e81–e94.PubMed
30.
Quijada, P., Salunga, H. T., Hariharan, N., Cubillo, J. D., El-Sayed, F. G., Moshref, M., et al. (2015). Cardiac stem cell hybrids enhance myocardial repair. Circulation Research, 117(8), 695–706.PubMedPubMedCentral
31.
Arena, R., Myers, J., Abella, J., Pinkstaff, S., Brubaker, P., Kitzman, D., et al. (2010). Defining the optimal prognostic window for cardiopulmonary exercise testing in patients with heart failure. Circulation Heart Failure, 3(3), 405–411.PubMedPubMedCentral
32.
Balady, G. J., Arena, R., Sietsema, K., Myers, J., Coke, L., Fletcher, G. F., et al. (2010). Clinician’s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation, 122(2), 191–225.PubMed
33.
Mancini, D. M., Eisen, H., Kussmaul, W., Mull, R., Edmunds Jr., L. H., & Wilson, J. R. (1991). Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation, 83(3), 778–786.PubMed
34.
Honold, J., Fischer-Rasokat, U., Seeger, F. H., Leistner, D., Lotz, S., Dimmeler, S., et al. (2013). Impact of intracoronary reinfusion of bone marrow-derived mononuclear progenitor cells on cardiopulmonary exercise capacity in patients with chronic postinfarction heart failure. Clinical Research in Cardiology: Official Journal of the German Cardiac Society, 102(9), 619–625.
35.
Nir, S. G., David, R., Zaruba, M., Franz, W. M., & Itskovitz-Eldor, J. (2003). Human embryonic stem cells for cardiovascular repair. Cardiovascular Research, 58(2), 313–323.PubMed
36.
Wong, S. S., & Bernstein, H. S. (2010). Cardiac regeneration using human embryonic stem cells: producing cells for future therapy. Regenerative Medicine, 5(5), 763–775.PubMed
37.
Rajasingh, J., Thangavel, J., Siddiqui, M. R., Gomes, I., Gao, X. P., Kishore, R., et al. (2011). Improvement of cardiac function in mouse myocardial infarction after transplantation of epigenetically-modified bone marrow progenitor cells. PLoS One, 6(7), e22550.PubMedPubMedCentral
38.
Rajasingh, J., Bord, E., Hamada, H., Lambers, E., Qin, G., Losordo, D. W., et al. (2007). STAT3-dependent mouse embryonic stem cell differentiation into cardiomyocytes: analysis of molecular signaling and therapeutic efficacy of cardiomyocyte precommitted mES transplantation in a mouse model of myocardial infarction. Circulation Research, 101(9), 910–918.PubMed
39.
Kawamura, M., Miyagawa, S., Miki, K., Saito, A., Fukushima, S., Higuchi, T., et al. (2012). Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation, 126(11 Suppl 1), S29–S37.PubMed
40.
Traverse, J. H., Henry, T. D., Pepine, C. J., Willerson, J. T., Zhao, D. X., Ellis, S. G., et al. (2012). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. Journal of the American Medical Association, 308(22), 2380–2389.PubMed
41.
Strauer, B. E., Brehm, M., Zeus, T., Kostering, M., Hernandez, A., Sorg, R. V., et al. (2002). Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation, 106(15), 1913–1918.PubMed
42.
Manginas, A., Goussetis, E., Koutelou, M., Karatasakis, G., Peristeri, I., Theodorakos, A., et al. (2007). Pilot study to evaluate the safety and feasibility of intracoronary CD133(+) and CD133(−) CD34(+) cell therapy in patients with nonviable anterior myocardial infarction. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography & Interventions, 69(6), 773–781.
43.
Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S. M., Li, B., et al. (2001). Bone marrow cells regenerate infarcted myocardium. Nature, 410(6829), 701–705.PubMed
44.
Stamm, C., Kleine, H. D., Choi, Y. H., Dunkelmann, S., Lauffs, J. A., Lorenzen, B., et al. (2007). Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. The Journal of Thoracic and Cardiovascular Surgery, 133(3), 717–725.PubMed
45.
Lader, J., Stachel, M., & Bu, L. (2017). Cardiac stem cells for myocardial regeneration: promising but not ready for prime time. Current Opinion in Biotechnology, 47, 30–35.PubMedPubMedCentral
46.
Gao, L. R., Chen, Y., Zhang, N. K., Yang, X. L., Liu, H. L., Wang, Z. G., et al. (2015). Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. BMC Medicine, 13, 162.PubMedPubMedCentral
47.
Amado, L. C., Saliaris, A. P., Schuleri, K. H., St John, M., Xie, J. S., Cattaneo, S., et al. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 102(32), 11474–11479.PubMedPubMedCentral
48.
Quevedo, H. C., Hatzistergos, K. E., Oskouei, B. N., Feigenbaum, G. S., Rodriguez, J. E., Valdes, D., et al. (2009). Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proceedings of the National Academy of Sciences of the United States of America, 106(33), 14022–14027.PubMedPubMedCentral
49.
Goretti, E., Wagner, D. R., & Devaux, Y. (2014). Role of MicroRNAs in endothelial progenitor cells: implication for cardiac repair. Journal of Stem Cells, 9(2), 107–115.PubMed
50.
Meneveau, N., Deschaseaux, F., Seronde, M. F., Chopard, R., Schiele, F., Jehl, J., et al. (2011). Presence of endothelial colony-forming cells is associated with reduced microvascular obstruction limiting infarct size and left ventricular remodelling in patients with acute myocardial infarction. Basic Research in Cardiology, 106(6), 1397–1410.PubMed
51.
Kanazawa, H., Tseliou, E., Malliaras, K., Yee, K., Dawkins, J. F., De Couto, G., et al. (2015). Cellular postconditioning: allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. Circulation Heart Failure, 8(2), 322–332.PubMedPubMedCentral
52.
Wohrle, J., von Scheidt, F., Schauwecker, P., Wiesneth, M., Markovic, S., Schrezenmeier, H., et al. (2013). Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in Patients with Acute Myocardial Infarction (SCAMI) trial. Clinical Research in Cardiology: Official Journal of the German Cardiac Society, 102(10), 765–770.
53.
Porto, I., De Maria, G. L., Leone, A. M., Dato, I., D'Amario, D., Burzotta, F., et al. (2013). Endothelial progenitor cells, microvascular obstruction, and left ventricular remodeling in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. The American Journal of Cardiology, 112(6), 782–791.PubMed
54.
Grieve, S. M., Bhindi, R., Seow, J., Doyle, A., Turner, A. J., Tomka, J., et al. (2010). Microvascular obstruction by intracoronary delivery of mesenchymal stem cells and quantification of resulting myocardial infarction by cardiac magnetic resonance. Circulation Heart Failure, 3(3), e5–e6.PubMed
55.
Gleeson, B. M., Martin, K., Ali, M. T., Kumar, A. H., Pillai, M. G., Kumar, S. P., et al. (2015). Bone marrow-derived mesenchymal stem cells have innate procoagulant activity and cause microvascular obstruction following intracoronary delivery: amelioration by antithrombin therapy. Stem Cells (Dayton, Ohio), 33(9), 2726–2737.
56.
Liu, B., Duan, C. Y., Luo, C. F., Ou, C. W., Sun, K., Wu, Z. Y., et al. (2014). Effectiveness and safety of selected bone marrow stem cells on left ventricular function in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. International Journal of Cardiology, 177(3), 764–770.PubMed
57.
Yu, C. W., Choi, S. C., Hong, S. J., Choi, J. H., Park, C. Y., Kim, J. H., et al. (2013). Cardiovascular event rates in patients with ST-elevation myocardial infarction were lower with early increases in mobilization of Oct4(high)Nanog(high) stem cells into the peripheral circulation during a 4-year follow-up. International Journal of Cardiology, 168(3), 2533–2539.PubMed
58.
Gyongyosi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., et al. (2015). Meta-Analysis of Cell-based Cardiac Studies (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circulation Research, 116(8), 1346–1360.PubMedPubMedCentral
59.
Heldman, A. W., DiFede, D. L., Fishman, J. E., Zambrano, J. P., Trachtenberg, B. H., Karantalis, V., et al. (2014). Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. Journal of the American Medical Association, 311(1), 62–73.PubMed
60.
Nasseri, B. A., Ebell, W., Dandel, M., Kukucka, M., Gebker, R., Doltra, A., et al. (2014). Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial. European Heart Journal, 35(19), 1263–1274.PubMed
61.
Honold, J., DeRosa, S., Spyridopoulos, I., Fischer-Rasokat, U., Seeger, F. H., Leistner, D., et al. (2013). Comparison of the Seattle heart failure model and cardiopulmonary exercise capacity for prediction of death in patients with chronic ischemic heart failure and intracoronary progenitor cell application. Clinical Cardiology, 36(3), 153–159.PubMedPubMedCentral
62.
Bartunek, J., Behfar, A., Dolatabadi, D., Vanderheyden, M., Ostojic, M., Dens, J., et al. (2013). Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic Stem Cell Therapy in Heart Failure) multicenter randomized trial with lineage-specified biologics. Journal of the American College of Cardiology, 61(23), 2329–2338.PubMed
63.
Xiong, Q., Ye, L., Zhang, P., Lepley, M., Swingen, C., Zhang, L., et al. (2012). Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells. Circulation Research, 111(4), 455–468.PubMedPubMedCentral
64.
Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.PubMed
65.
Wang, Z., Wang, L., Su, X., Pu, J., Jiang, M., & He, B. (2017). Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Stem cell research & therapy, 8(1), 21.
66.
Wei, X., Yang, X., Han, Z. P., Qu, F. F., Shao, L., & Shi, Y. F. (2013). Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacologica Sinica, 34(6), 747–754.PubMedPubMedCentral
67.
Noiseux, N., Gnecchi, M., Lopez-Ilasaca, M., Zhang, L., Solomon, S. D., Deb, A., et al. (2006). Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Molecular Therapy: the Journal of the American Society of Gene Therapy, 14(6), 840–850.
68.
Gnecchi, M., Zhang, Z., Ni, A., & Dzau, V. J. (2008). Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research, 103(11), 1204–1219.PubMedPubMedCentral
69.
Chou, S. H., Lin, S. Z., Kuo, W. W., Pai, P., Lin, J. Y., Lai, C. H., et al. (2014). Mesenchymal stem cell insights: prospects in cardiovascular therapy. Cell Transplantation, 23(4–5), 513–529.PubMed
70.
Karantalis, V., & Hare, J. M. (2015). Use of mesenchymal stem cells for therapy of cardiac disease. Circulation Research, 116(8), 1413–1430.PubMedPubMedCentral
71.
Oh, J. Y., Kim, M. K., Shin, M. S., Lee, H. J., Ko, J. H., Wee, W. R., et al. (2008). The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem cells (Dayton, Ohio), 26(4), 1047–1055.
72.
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5(1), 54–63.PubMedPubMedCentral
73.
Forte, A., Finicelli, M., Mattia, M., Berrino, L., Rossi, F., De Feo, M., et al. (2008). Mesenchymal stem cells effectively reduce surgically induced stenosis in rat carotids. Journal of Cellular Physiology, 217(3), 789–799.PubMed
74.
Chen, L., Tredget, E. E., Wu, P. Y., & Wu, Y. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One, 3(4), e1886.PubMedPubMedCentral
75.
Khan, M., Nickoloff, E., Abramova, T., Johnson, J., Verma, S. K., Krishnamurthy, P., et al. (2015). Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circulation Research, 117(1), 52–64.PubMedPubMedCentral
76.
Barile, L., Lionetti, V., Cervio, E., Matteucci, M., Gherghiceanu, M., Popescu, L. M., et al. (2014). Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovascular Research, 103(4), 530–541.PubMed
77.
Singla, D. K. (2016). Stem cells and exosomes in cardiac repair. Current Opinion in Pharmacology, 27, 19–23.PubMed
78.
Lyu, L., Wang, H., Li, B., Qin, Q., Qi, L., Nagarkatti, M., et al. (2015). A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 89(Pt B), 268–279.PubMedPubMedCentral
79.
Cervio, E., Barile, L., Moccetti, T., & Vassalli, G. (2015). Exosomes for intramyocardial intercellular communication. Stem Cells International, 2015, 482171.PubMedPubMedCentral
80.
Zhou, R., Chen, K. K., Zhang, J., Xiao, B., Huang, Z., Ju, C., et al. (2018). The decade of exosomal long RNA species: an emerging cancer antagonist. Molecular Cancer, 17(1), 75.PubMedPubMedCentral
81.
Chang, W., Lee, C. Y., Park, J. H., Park, M. S., Maeng, L. S., Yoon, C. S., et al. (2013). Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. Journal of Veterinary Science, 14(1), 69–76.PubMedPubMedCentral
82.
Chang, W., Kim, R., Park, S. I., Jung, Y. J., Ham, O., Lee, J., et al. (2015). Enhanced healing of rat calvarial bone defects with hypoxic conditioned medium from mesenchymal stem cells through increased endogenous stem cell migration via regulation of ICAM-1 targeted-microRNA-221. Molecules and Cells, 38(7), 643–650.PubMedPubMedCentral
83.
Sadek, H., Hannack, B., Choe, E., Wang, J., Latif, S., Garry, M. G., et al. (2008). Cardiogenic small molecules that enhance myocardial repair by stem cells. Proceedings of the National Academy of Sciences of the United States of America, 105(16), 6063–6068.PubMedPubMedCentral
84.
Prathipati, P., Nandi, S. S., & Mishra, P. K. (2017). Stem cell-derived exosomes, autophagy, extracellular matrix turnover, and miRNAs in cardiac regeneration during stem cell therapy. Stem Cell Reviews, 13(1), 79–91.PubMedCentral
85.
Nollet, E., Hoymans, V. Y., Van Craenenbroeck, A. H., Vrints, C. J., & Van Craenenbroeck, E. M. (2016). Improving stem cell therapy in cardiovascular diseases: the potential role of microRNA. American Journal of Physiology Heart and Circulatory Physiology, 311(1), H207–H218.PubMed
86.
Marquis-Gravel, G., Stevens, L. M., Mansour, S., Avram, R., & Noiseux, N. (2014). Stem cell therapy for the treatment of nonischemic cardiomyopathy: a systematic review of the literature and meta-analysis of randomized controlled trials. Canadian Journal of Cardiology, 30(11), 1378–1384.
87.
Stehlik, J., Edwards, L. B., Kucheryavaya, A. Y., Benden, C., Christie, J. D., Dobbels, F., et al. (2011). The registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report—2011. Journal of Heart & Lung Transplantation the Official Publication of the International Society for Heart Transplantation, 30(10), 1078.
88.
Fischerrasokat, U., Assmus, B., Seeger, F. H., Honold, J., Leistner, D., Fichtlscherer, S., et al. (2009). A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy. Circulation Heart Failure, 2(5), 417.
89.
Seth, S., Bhargava, B., Narang, R., Ray, R., Mohanty, S., Gulati, G., et al. (2010). The ABCD (autologous bone marrow cells in dilated cardiomyopathy) trial : a long-term follow-up study. Journal of the American College of Cardiology, 55(15), 1643–1644.PubMed
90.
Vrtovec, B., Poglajen, G., Sever, M., Lezaic, L., Domanovic, D., Cernelc, P., et al. (2011). Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure, 17(4), 272.PubMed
91.
Vrtovec, B., Poglajen, G., Lezaic, L., Sever, M., Domanovic, D., Cernelc, P., et al. (2013). Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients 5-year follow-up. Circulation Research, 112(1), 165.PubMed
92.
Sant'Anna, R. T., Fracasso, J., Valle, F. H., Castro, I., Nardi, N. B., Sant'Anna, J. R. M., et al. (2014). Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira De Cirurgia Cardiovascular Órgão Oficial Da Sociedade Brasileira De Cirurgia Cardiovascular, 29(3), 437–447.PubMedPubMedCentral
93.
Martino, H., Brofman, P., Greco, O., Bueno, R., Bodanese, L., Clausell, N., et al. (2015). Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal, 36(42), 2898.PubMed
94.
Lu, Y., Wang, Y., Lin, M., Zhou, J., Wang, Z., Jiang, M., et al. (2016). A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Research & Therapy, 7(1), 186.
95.
Maron, B. J. (2002). Hypertrophic cardiomyopathy: a systematic review. Journal of the American Medical Association, 287(10), 1308.PubMed
96.
Maron, B. J., Maron, M. S., & Semsarian, C. (2012). Genetics of hypertrophic cardiomyopathy after 20 years : clinical perspectives. Journal of the American College of Cardiology, 60(8), 705–715.PubMed
97.
Han, L., Li, Y., Tchao, J., Kaplan, A. D., Lin, B., Li, Y., et al. (2014). Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Cardiovascular Research, 104(2), 258–269.PubMedPubMedCentral
98.
Suzuki, K., Murtuza, B., Beauchamp, J. R., Brand, N. J., Barton, P. J., Varela-Carver, A., et al. (2004). Role of interleukin-1beta in acute inflammation and graft death after cell transplantation to the heart. Circulation, 110(11 Suppl 1), Ii219–Ii224.PubMed
99.
Narita, T., & Suzuki, K. (2015). Bone marrow-derived mesenchymal stem cells for the treatment of heart failure. Heart Failure Reviews, 20(1), 53–68.PubMed
100.
Lai, R. C., Chen, T. S., & Lim, S. K. (2011). Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regenerative Medicine, 6(4), 481–492.PubMed
101.
Giraud, M. N., Guex, A. G., & Tevaearai, H. T. (2012). Cell therapies for heart function recovery: focus on myocardial tissue engineering and nanotechnologies. Cardiology Research and Practice, 2012, 971614.PubMedPubMedCentral
102.
Bai, Y., Sun, T., & Ye, P. (2010). Age, gender and diabetic status are associated with effects of bone marrow cell therapy on recovery of left ventricular function after acute myocardial infarction: a systematic review and meta-analysis. Ageing Research Reviews, 9(4), 418–423.PubMed
Metadaten
Titel
Regenerative Therapy for Cardiomyopathies
verfasst von
Zi Wang
Xuan Su
Muhammad Ashraf
Il-man Kim
Neal L. Weintraub
Meng Jiang
Yaoliang Tang
Publikationsdatum
09.05.2018
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 5/2018
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-018-9807-z

Weitere Artikel der Ausgabe 5/2018

Journal of Cardiovascular Translational Research 5/2018 Zur Ausgabe

Review Paper

Endothelial Progenitor Cells in Heart Failure: an Authentic Expectation for Potential Future Use and a Lack of Universal Definition

Original Article

Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes Promotes Repair in Ischemic Myocardium

Review

Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy

Original Article

Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular Dystrophic Mice

Original Article

Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes for Angiogenesis

Review Paper

The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Sind Betablocker auch für ältere herzschwache Personen nützlich?

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen